G1 Therapeutics

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of cancer. The company's product pipeline includes: trilaciclib, a short-acting cyclin-dependent kinases (CDK) 4/6 inhibitor which is developing to be administered intravenously prior to chemotherapy; G1T38, a potential oral CDK4/6 inhibitor, to be used in combination with other targeted therapies to treat multiple cancers; and G1T48, a potential oral Selective Estrogen Receptor Degrader which is in preclinical development stage for the treatment of ER-positive, or ER+, HER2- breast cancer.
  • TickerGTHX
  • ISINUS3621LQ1099
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

David Nierengarten ...
  • Jeffrey La Rosa

Not so Fas(lodex)! Here Comes G1T48

1 director sold

A director at G1 Therapeutics Inc sold 10,000 shares at 59.597USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ValuEngine Rating and Forecast Report for GTHX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch